Previous 10 | Next 10 |
BMEZ was one of the best performing funds in 2020, the year it launched as it hit the market at the right time. This success did not carry over to 2021, as it was one of the seemingly few funds to produce losses for the year. It has been an even tougher go as we enter into 2022, a...
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that two abstracts – including...
Gainers: uCloudlink Group (NASDAQ:UCL) +15%. Quantum-Si Incorporated QSI +10%. Micron Technology MU +7%. Braze BRZE +6%. JAKKS Pacific (NASDAQ:JAKK) +6%. Losers: CytomX Therapeutics CTMX -29%. DBV Technologies (NASDAQ:DBVT) -13%. Sigilon Therape...
Sigilon Therapeutics (NASDAQ:SGTX) announces a strategic reprioritization to focus on MPS-1 and diabetes. In November, the company reported that fibrosed spheres were observed during a retrieval procedure for the third patient enrolled in its Phase 1/2 study of SIG-001 in hemophilia A. SGTX p...
- Company plans to prioritize MPS-1 and diabetes with continued focus on platform optimization – - Workforce reduction of approximately 38% – - Anticipated cash runway extended into 2024 – CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWI...
Gainers: Stitch Fix (NASDAQ:SFIX) +2%. Fate Therapeutics (NASDAQ:FATE) +2%. Frequency Therapeutics (NASDAQ:FREQ) +1%. Criteo (NASDAQ:CRTO) +1%. EVgo (NASDAQ:EVGO) +1%. Losers: Nexters (NASDAQ:GDEV) -3%. Ocular Therapeutix (NASDAQ:OCUL) -2%. Sig...
Sigilon Therapeutics (SGTX -3.3%) is trading lower after Jefferies downgraded the stock to Hold from Buy in reaction to the company’s announcement on Monday about a case of fibrosis found in its Phase 1/2 study for SIG-001 in hemophilia A. Noting that the event was “unexpec...
Having observed fibrosed spheres in a patient who underwent its Phase 1/2 study of SIG-001 in hemophilia A, Sigilon Therapeutics (NASDAQ:SGTX) says that the findings could have an impact on the timing of the start of dosing in a future Phase 1/2 trial of SIG-005 in mucopolysaccharidosis type ...
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported that fibrosed spheres were observed dur...
Sigilon Therapeutics (NASDAQ:SGTX): Q3 GAAP EPS of -$0.63 beats by $0.03. Revenue of $1.95M (-53.6% Y/Y) misses by $0.95M. Press Release For further details see: Sigilon Therapeutics EPS beats by $0.03, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
Sigilon Therapeutics Inc. Company Name:
SGTX Stock Symbol:
NASDAQ Market:
Sigilon Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / July 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chase Corporation (NYSE:CCF)'s sale...
NEW YORK, NY / ACCESSWIRE / July 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CIRCOR International, Inc. (NYSE: CIR...
NEW YORK, NY / ACCESSWIRE / July 12, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chinook Therapeutics, Inc. (NAS...